17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer
Author:
Affiliation:
1. The Chinese University of Hong Kong, China
Publisher
FapUNIFESP (SciELO)
Subject
Urology
Link
http://www.scielo.br/pdf/ibju/v31n3/v31n3a03.pdf
Reference12 articles.
1. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone;Kurth K;J Urol,1997
2. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin;Akaza H;Cancer Chemother Pharmacol,1992
3. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer: The Hokkaido University Bladder Cancer Collaborative Group;Shinohara N;Cancer Chemother Pharmacol,1994
4. Tur vs TUR plus adriamycin in patients with superficial bladder cancer-a five-year follow-up;Burk K;Prog Clin Biol Res,1989
5. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients;Huland H;J Urol,1990
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association;Urologic Oncology: Seminars and Original Investigations;2024-09
2. Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis;Clinical Genitourinary Cancer;2020-04
3. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population;Medicine;2016-02
4. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2012-07
5. Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer;Expert Opinion on Investigational Drugs;2011-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3